Watson’s New Tele-Detailing Take on Primary Care
This article was originally published in The Pink Sheet Daily
Executive Summary
Watson Pharmaceuticals is looking at using its telemarketing and drug distribution arm to reach out to primary care docs for new drugs.
You may also be interested in...
Reeling From Ferrlecit Loss, Watson Revamps Branded Sales Strategy
Insurance coverage was an "obstacle to launch," for Rapaflo and Gelnique, but the outlook is much better for 2010, says Watson.
Reeling From Ferrlecit Loss, Watson Revamps Branded Sales Strategy
Insurance coverage was an "obstacle to launch," for Rapaflo and Gelnique, but the outlook is much better for 2010, says Watson.
Watson Seeks Partner For Rapaflo: Is There Still A Market For “Me-Too’s”?
Watson is in discussions with potential primary care partners for its newly approved benign prostatic hyperplasia therapy Rapaflo (silodosin)